MedTrace Logo

Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer

NCT01656460 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-07-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and toxicity stereotactic body radiation (SBRT) as consolidation following standard chemoradiation for patients with stage III non-small cell lung cancer.

Conditions

Interventions

RADIATION

Stereotactic radiation Arm 1

Dose Levels Dose per Fraction Total Dose 1 8 Gy 16 Gy

RADIATION

Stereotactic radiation Arm 2

Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy

RADIATION

Stereotactic radiation Arm 3

Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy

RADIATION

Stereotactic radiation Arm 4

Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy

Sponsors & Collaborators

  • Memorial Hospital of Rhode Island

    collaborator OTHER

  • Dr Thomas DiPetrillo

    lead OTHER

Principal Investigators

  • Howard Safran, MD · BrUOG Study Chair

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-03-31
Completion
2017-05-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01656460 on ClinicalTrials.gov